# Dose-Escalation and Safety Trial of YN968D1

> **NCT01497704** · PHASE1,PHASE2 · COMPLETED · sponsor: **Elevar Therapeutics** · enrollment: 55 (actual)

## Conditions studied

- Cancer Patients With Solid Tumors

## Interventions

- **DRUG:** YN968D1

## Key facts

- **NCT ID:** NCT01497704
- **Lead sponsor:** Elevar Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-04
- **Primary completion:** 2015-02
- **Final completion:** 2015-05
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2017-10-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01497704

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01497704, "Dose-Escalation and Safety Trial of YN968D1". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01497704. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*